Voluntary wheel running decreases amyloidogenic pathway and rescues cognition and mitochondrial energy metabolism in middle-aged female 3xTg-AD mouse model of Alzheimer's disease
Restricted accessResearch articleFirst published online November, 2024
Voluntary wheel running decreases amyloidogenic pathway and rescues cognition and mitochondrial energy metabolism in middle-aged female 3xTg-AD mouse model of Alzheimer's disease
Evidence supports the neuroprotective effects of physical activity, either in experimental animal models or humans. However, the biological mechanisms by which physical exercise modulates dementia and Alzheimer's disease (AD) progression are still unclear.
Objective
This study investigated whether long-term (6 months) of voluntary wheel running induces neuroprotective effects in the pathogenesis of AD in middle-aged (8 months) female mice, focusing on energy metabolism.
Methods
A genetic mice model of AD (3xTg-AD) that performed wheel running presented changes in body metabolism and muscle oxidative profile, as well as restored discriminative and non-associative retention memories, evaluated by novel object recognition and open field tasks, respectively.
Results
In the hippocampus, these mice exhibited reduced levels of amyloidogenic AβPPβ fragment, phospho-Tau protein and phospho-Akt (activated form), without changes in phospho-AMPK (activated form). In addition, hippocampal mitochondria presented a restored respiratory function, characterized by lower coupling degree and weak contribution from complex I found in 3xTg-AD mice.
Conclusions
The results demonstrated that voluntary exercise improves cognitive parameters and biochemical hallmarks of AD, modulates Akt activation and enhances mitochondrial energy metabolism in hippocampus of middle-aged 3xTg-AD female mice, thereby reinforcing the neuroprotective role of physical exercise and the involvement of mitochondria in the etiology of the AD.
TengZ. Novel development and prospects in pathogenesis, diagnosis, and therapy of Alzheimer's disease. J Alzheimers Dis Rep2024; 8: 345–354.
3.
HardyJSelkoeDJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science2002; 297: 353–356.
4.
HardyJ. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem2009; 110: 1129–1134.
5.
HampelHVassarRDe StrooperB, et al.The β-secretase BACE1 in Alzheimer's disease. Biol Psychiatry2021; 89: 745–756.
6.
LiangKYMintunMAFaganAM, et al.Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol2010; 68: 311–318.
7.
EdwardsGAGamezNEscobedoGJr, et al.Modifiable risk factors for Alzheimer's disease. Front Aging Neurosci2019; 11: 146.
8.
SwerdlowRH. Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis2018; 62: 1403–1416.
9.
WeidlingIWSwerdlowRH. Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis. Exp Neurol2020; 330: 113321.
10.
TeradaTObiTBunaiT, et al.In vivo mitochondrial and glycolytic impairments in patients with Alzheimer disease. Neurology2020; 94: e1592–e1604.
11.
Flores-LeónMPérez-DomínguezMGonzález-BarriosR, et al.Palmitic acid-induced NAD+ depletion is associated with the reduced function of SIRT1 and increased expression of BACE1 in hippocampal neurons. Neurochem Res2019; 44: 1745–1754.
12.
RyuW-IBormannMKShenM, et al.Brain cells derived from Alzheimer’s disease patients have multiple specific innate abnormalities in energy metabolism. Mol Psychiatry2021; 26: 5702–5714.
13.
Camacho-CastilloLPhillips-FarfánBVRosas-MendonzaG, et al.Increased oxidative stress contributes to enhance brain amyloidogenesis and blunts energy metabolism in sucrose-fed rat: effect of AMPK activation. Sci Rep2021; 11: 19547.
14.
PinhoCMTeixeiraPFGlaserE. Mitochondrial import and degradation of amyloid-β peptide. Biochim Biophys Acta2014; 1837: 1069–1074.
15.
WilkinsHMSwerdlowRH. Amyloid precursor protein processing and bioenergetics. Brain Res Bull2017; 133: 71–79.
16.
PedrosIPatracaIMartinezN, et al.Molecular links between early energy metabolism alterations and Alzheimer's disease. Front Biosci (Landmark Ed)2016; 21: 8–19.
17.
BarnesDEYaffeK. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol2011; 10: 819–828.
18.
FrancisNRobisonLSPopescuDL, et al.Voluntary wheel running reduces amyloid-β42 and rescues behavior in aged Tg2576 mouse model of Alzheimer's disease. J Alzheimers Dis2020; 73: 359–374.
19.
ChoJShinMKKimD, et al.Treadmill running reverses cognitive declines due to Alzheimer disease. Med Sci Sports Exerc2015; 47: 1814–1824.
20.
HamerMChidaY. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med2009; 39: 3–11.
21.
JavonilloDITranKMPhanJ, et al.Systematic phenotyping and characterization of the 3xTg-AD mouse model of Alzheimer's disease. Front Neurosci2022; 15: 785276.
22.
WisloffUHelgerudJKemiOJ, et al.Intensity-controlled treadmill running in rats: vO(2 max) and cardiac hypertrophy. Am J Physiol Heart Circ Physiol2001; 280: H1301–H1310.
23.
BradfordMM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem1976; 72: 248–254.
24.
SpinazziMCasarinAPertegatoV, et al.Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc2012; 7: 1235–1234.
25.
VulczakASouzaAOFerrariGD, et al.Moderate exercise modulates tumor metabolism of triple-negative breast cancer. Cells2020; 9: 628.
26.
ViannaMRAlonsoMViolaH, et al.Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat. Learn Mem2000; 7: 333–340.
27.
MoriceEAndreaeLCCookeSF, et al.Preservation of long-term memory and synaptic plasticity despite short-term impairments in the Tc1 mouse model of down syndrome. Learn Mem2008; 15: 492–450.
28.
LueptowLM. Novel object recognition test for the investigation of learning and memory in mice. J Vis Exp2017; 126: 55718.
29.
BevinsRABesheerJ. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study ‘recognition memory’. Nat Protoc2006; 1: 1306–1311.
30.
PestaDGnaigerE. High-resolution respirometry: OXPHOS protocols for human cells and permeabilized fibers from small biopsies of human muscle. Methods Mol Biol2012; 810: 25–58.
31.
LarsenSNielsenJHansenCN, et al.Biomarkers of mitochondrial content in skeletal muscle of healthy young human subjects. J Physiology2012; 590: 3349–3360.
32.
ŠkopVGuoJLiuN, et al.The metabolic cost of physical activity in mice using a physiology-based model of energy expenditure. Mol Metab2023; 71: 101699.
33.
YangYWangJZ. Nature of tau-associated neurodegeneration and the molecular mechanisms. J Alzheimers Dis2018; 62: 1305–1317.
34.
CongdonEEJiCTetlowAM, et al.Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol2023; 19: 715–736.
35.
O'BrienRJWongPC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci2011; 34: 185–204.
36.
MarinTLGongolBZhangF, et al.AMPK Promotes mitochondrial biogenesis and function by phosphorylating the epigenetic factors DNMT1, RBBP7, and HAT1. Sci Signal2017; 10: eaaf7478.
37.
HerzigSShawRJ. AMPK: guardian of metabolism and mitochondrial homeostasis. Nat Rev Mol Cell Biol2018; 19: 121–135.
38.
CulmseeCMonningJKempBE, et al.AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci2001; 17: 45–58.
39.
WangLZhouKFuZ, et al.Brain development and Akt signaling: the crossroads of signaling pathway and neurodevelopmental diseases. J Mol Neurosci2017; 61: 379–384.
40.
FlanneryPJTrushinaE. Mitochondrial dysfunction in Alzheimer’s disease and progress in mitochondria-targeted therapeutics. Curr Behav Neurosci Rep2019; 6: 88–102.
41.
BelfioreRRodinAFerreiraE, et al.Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. Aging Cell2019; 18: e12873.
42.
KimDChoJKangH. Protective effect of exercise training against the progression of Alzheimer's disease in 3xTg-AD mice. Behav Brain Res2019; 374: 112105.
43.
LinTWShihYHChenSJ, et al.Running exercise delays neurodegeneration in amygdala and hippocampus of Alzheimer's disease (APP/PS1) transgenic mice. Neurobiol Learn Mem2015; 118: 189–197.
44.
WangGZhouHHLuoL, et al.Voluntary wheel running is capable of improving cognitive function only in the young but not the middle-aged male APPSwe/PS1De9 mice. Neurochem Int2021; 145: 105010.
45.
BarhaCKLiu-AmbroseT. Sex differences in exercise efficacy: is midlife a critical window for promoting healthy cognitive aging?FASEB J2020; 34: 11329–11336.
46.
LiuYChuJMTYanT, et al.Short-term resistance exercise inhibits neuroinflammation and attenuates neuropathological changes in 3xTg Alzheimer's disease mice. J Neuroinflammation2020; 17: 4.
47.
CamposHCRibeiroDEHashiguchiD, et al.Neuroprotective effects of resistance physical exercise on the APP/PS1 mouse model of Alzheimer's disease. Front Neurosci2023; 17: 1132825.
48.
JafarzadehGShakerianSFarboodY, et al.Effects of eight weeks of resistance exercises on neurotrophins and Trk receptors in Alzheimer model male Wistar rats. Basic Clin Neurosci2021; 12: 349–359.
49.
AzevedoCVHashiguchiDCamposHC, et al.The effects of resistance exercise on cognitive function, amyloidogenesis, and neuroinflammation in Alzheimer's disease. Front Neurosci2023; 17: 1131214.
50.
JackCRJrBennettDABlennowK, et al.NIA-AA Research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018; 14: 535–562.
51.
HanseeuwBJBetenskyRAJacobsHIL, et al.Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol2019; 76: 915–924.
52.
JackCRWisteHJBothaH, et al.The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain2019; 142: 3230–3242.
53.
JackCRJrKnopmanDSJagustWJ, et al.Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol2013; 12: 207–216.
54.
OddoSCaccamoAShepherdJD, et al.Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular abeta and synaptic dysfunction. Neuron2003; 39: 409–421.
55.
HassCLamereCACapellA, et al.The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med1995; 1: 1291–1296.
56.
LuYDongYTuckerD, et al.Treadmill exercise exerts neuroprotection and regulates microglial polarization and oxidative stress in a streptozotocin-induced rat model of sporadic Alzheimer's disease. J Alzheimers Dis2017; 56: 1469–1484.
57.
AtlanteAValentiD. Mitochondrial complex I and β-amyloid peptide interplay in Alzheimer's disease: a critical review of new and old little regarded findings. Int J Mol Sci2023; 24: 15951.
58.
ManczakMReddyPH. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet2012; 21: 5131–5146.
59.
ResendeRMoreiraPIProençaT, et al.Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radic Biol Med2008; 44: 2051–2057.
60.
DavidDCHauptmannSScherpingI, et al.Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem2005; 280: 23802–23814.
61.
YaoJIrwinRWZhaoL, et al.Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A2009; 106: 14670–14675.
62.
BirnbaumJHWannerDGietlAF, et al.Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer's disease patients. Stem Cell Res2018; 27: 121–130.
63.
EckertASchmittKGotzJ. Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity. Alzheimers Res Ther2011; 3: 15.
64.
BerryBJTrewinAJAmitranoAM, et al.Use the protonmotive force: mitochondrial uncoupling and reactive oxygen species. J Mol Biol2018; 430: 3873–3891.
65.
SalminenAKaarnirantaKHaapasaloA, et al.AMP-activated protein kinase: a potential player in Alzheimer's disease. J Neurochem2011; 118: 460–474.
66.
WonJSImYBKimJ, et al.Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. Biochem Biophys Res Commun2010; 399: 487–491.
67.
DonmezGWangDCohenDE,et al.SIRT1 Suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10 [retracted in: cell 2014; 158: 959]. Cell2010; 142: 320–332.
68.
KuhnPHWangHDislichB, et al.ADAM10 Is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J2010; 29: 3020–3032.
69.
SonSMShinHJByunJ, et al.Metformin facilitates amyloid-β generation by β- and γ-secretases via autophagy activation. J Alzheimers Dis2016; 51: 1197–1208.
70.
ChenYZhouKWangR, et al.Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A2009; 106: 3907–3912.
71.
DomiseMDidierSMarinangeliC, et al.AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep2016; 6: 26758.
72.
GiebultowiczJKapahiP. Circadian clocks and metabolism: the nutrient-sensing AKT and TOR pathways make the link. Curr Biol2010; 20: R608–R609.
73.
YangSPascual-GuiralSPonceR, et al.Reducing the levels of Akt activation by PDK1 knock-in mutation protects neuronal cultures against synthetic amyloid-beta peptides. Fron Aging Neurosci2018; 9: 435.
74.
PietriMDakowskiCHannaouiS, et al.PDK1 Decreases TACE-mediated α-secretase activity and promotes disease progression in prion and Alzheimer's diseases. Nat Med2013; 19: 1124–1131.
